1st Edition
50 Landmark Papers every Breast Surgeon Should Know
There has been an exponential increase in the volume and quality of published research relating to breast disease over the past decades. This book identifies the 50 key scientific articles in the field of breast disease and breast surgery and examines their importance and impact on current clinical care.
Among thousands of articles, a small fraction are truly 'game changing'. Such studies form the foundations of breast surgery today, and the selection of papers within this book provide the 50 landmark papers every 21st-century breast surgeon needs to know. A commentary to each carefully selected paper explains why these papers are so important, thus providing every surgeon with the foundation stones of knowledge in this fast-moving area.
A valuable reference not only to the established surgeon, but also to breast surgery residents and trainees, as well as to more experienced surgeons as they continue to learn new techniques and approaches and to improve their knowledge of breast disease and treatments. The papers provide an evidence-based resource for those surgeons preparing for professional exams and may inspire clinicians to produce new research.
Section One: Epidemiology
1. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence
Collaborative Group on Hormonal Factors in Breast Cancer
Commentary by Toral Gathani and Isobel Barnes
2. Moderate Alcohol Intake and Cancer Incidence in Women
Allen N, Beral V, Cassabone D, Kan SW, Reeves GK, Brown A, Green J on behalf of the Million Women Study Collaborators
Commentary by Toral Gathani and Isobel Barnes
Section Two: Screening and Prevention
3. Tamoxifen for Prevention of Breast Cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (NASBP P-1)
Fisher B, Costantino J, Wickerman D, et al
Commentary by Andrew Kilshaw and Lynda Wyld
4. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit.
Tabar L, Fagerberg G, Duffy SW, et al
Commentary by Alasdair Findlay and Lynda Wyld
5. The benefits and harms of breast cancer screening: an independent review
Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M.
Commentary by Colin McIlmunn and Stuart MacIntosh
Section Three: Diagnostic Imaging
6. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening (DMIST)
Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D’Orsi C, Jong R, Rebner M.
Commentary by Jonathan James, Mariana Matias and Nisha Sharma
7. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
Leach MO, Boggis CRM, Dixon AK, Easton DF, et al
Commentary by Jonathan James, Mariana Matias and Nisha Sharma
8. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, Hanby A, Brown J
Commentary by Jonathan James, Mariana Matias and Nisha Sharma
Section Four: Surgery: Mastectomy versus conservation
9. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N
Commentary by Bahar Mirshekar-Syahkal and John Benson
10. The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast Conserving Therapy: A Meta-Analysis
Houssami N, Macaskill P, Marinovich ML, Morrow M
Commentary by Leah Kim and Mehra Golshan
11. Ten year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study
van Maaren MC, de Munck L, de Back GH, Jobsen J, van Dalen T, Poortmans P, Strobbe LC, Siesling S.
Commentary by Ismail Jatoi and John Benson
Section Five: De-escalation of Axillary Surgery
12. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.
Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N
Commentary by Eilidh Bruce and Beatrix Elsberger
13. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE, Ballman KV, McCall L, et al.
Commentary by Eilidh Bruce and Beatrix Elsberger
14. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Donker M, van Tienhoven G, Straver ME, et al
Commentary by Eilidh Bruce and Beatrix Elsberger
15. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial
Boughey JC, Suman VJ, Mittendorf EA, et al.
Commentary by Eilidh Bruce and Beatrix Elsberger
Section Six: Oncoplastic Breast Surgery / Breast Reconstruction
16. Planning and use of therapeutic mammaplasty-Nottingham approach
S J McCulley and R D Macmillan
Commentary by Danielle Banfield and Shelley Potter
17. Oncoplastic breast‐conserving surgery for women with primary breast cancer
Nanda A, Hu J, Hodgkinson S, Ali S, Rainsbury R, Roy PG.
Commentary by Katherine Fairhurst and Shelley Potter
18. Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study
Potter et al
Commentary by Danielle Banfield and Shelley Potter
19. Improving Breast Cancer Surgery: A Classification and Quadrant per Quadrant Atlas for Oncoplastic Surgery
Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM
Commentary by David Stark and Shelley Potter
Section Seven: Breast cancer genomics and prognostic tools
20. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Therese Sørlie, Charles M. Perou, Robert Tibshirani, Turid Aas, Stephanie Geisler, Hilde Johnsen, et al.
Commentary by Cliona Kirwan and Rachel Foster
21. Comprehensive molecular portraits of human breast tumours
The cancer Genome Atlas Network
Commentary by Rachel Foster and Cliona Kirwan
22. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fatima Cardoso, Laura J. van’t Veer, Jan Bogaerts, et al for the MINDACT investigators
Commentary by Cliona Kirwan and Rachel Foster
23. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (RxPonder)
K. Kalinsky, W.E. Barlow, J.R. Gralow, et al
Commentary by Cliona Kirwan and Rachel Foster
24. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer
Gordon C Wishart, Elizabeth M Azzato, David C Greenberg, Jem Rashbass, Olive Kearins, Gill Lawrence, Carlos Caldas, and Paul DP Pharoah
Commentary by Rachel Foster and Cliona Kirwan
Section Eight: Ductal Carcinoma In Situ
25. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
Esther H. Lips, Tapsi Kumar, Anargyros Megalios, Lindy L. Visser, Michael Sheinman, Angelo Fortunato, et al
Commentary by Thomas Seddon, Pavneet S Kohli and Tim Rattay
26. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the Sloane Project
Shaaban AM, Hilton B, Clements K, Provenzano E, Cheung S, Wallis MG, Sawyer ES, Thomas JS, Hanby AM, Pinder SE, Thompson AM
Commentary by Stacey Carter, Elizabeth Bonefas, Karen Clements and Alastair Thompson
27. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD
Commentary by Nicole James and Gurdeep Mannu
28. A prognostic index for ductal carcinoma in situ of the breast.
Silverstein MJ, Poller D, Craig PH, et al
Commentary by Amit Agrawal and Mahmoud Soliman
Section Nine: Adjuvant Chemotherapy
29. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., Cutter, D., Darby, S., McGale, P., Taylor, C., Wang, Y. C., Bergh, J., Di Leo, A., Albain, K., Swain, S., Piccart, M., & Pritchard, K
Commentary by Jessica Banks, Lynda Wyld and Janet Brown
30. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. CREATE-X
N Masuda, Soo-Jung Lee, S Ohtani, Y-H Im, E-S Lee, I Yokota, K Kuroi, S-A Im, B-W Park, S-B Kim, Y Yanagita, and S Ohno et al
Commentary by Soudamini Nayak, Lynda Wyld and Janet Brown
Section Ten: Adjuvant Endocrine Therapy
31. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Commentary by Fiona James and Tom Hubbard
32. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor – positive breast cancer: ATLAS, a randomised trial
C Davies et al
Commentary by Fiona James and Tom Hubbard
33. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Prudence A Francis et al
Commentary by Fiona James and Douglas Ferguson
34. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
ATAC Trialist’s Group
Commentary by Alex Humphreys and Douglas Ferguson
Section Eleven: Immunotherapy / Systemic Therapy
35. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al & Herceptin Adjuvant (HERA) Trial Study Team
Commentary by Wilson Cheah Pui Fui and Ellen Copson
36. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Tutt ANJ, Garber JE, Kaufman B, et al
Commentary by Anthony Mark Monaghan and Ellen Copson
37. Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., et al
Commentary by Constantinos Savva and Ellen Copson
38. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, Huang, Mano, et al. for the KATHERINE Investigators
Commentary by Maclyn Augustine and Ellen Copson
Section Twelve: Adjuvant Radiotherapy
39. Breast-conserving surgery with or without irradiation in early breast cancer (PRIME II).
Ian H Kunkler et al
Commentary by Puteri Abdul Haris and David Dodwell
40. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Commentary by Puteri Abdul Haris and David Dodwell
41. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
H Bartelink et al
Commentary by Puteri Abdul Haris and David Dodwell
42. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Commentary by Puteri Abdul Haris and David Dodwell
43. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects; results from a multicentre, non-inferiority, randomised, phase 3 trial.
Brunt AM, et al
Commentary by Puteri Abdul Haris and David Dodwell
Section Thirteen: Bisphosphonates
44. Zoledronic acid as adjuvant therapy for breast cancer (does Adjuvant Zoledronic acid redUce REcurrence in patients with high risk, localised breast cancer), the AZURE trial
Robert Coleman, David Cameron, David Dodwell, et al on behalf of the AZURE investigators.
Commentary by Steven Wood, Emma Green and Janet Brown
45. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial
Eastell, R., Adams, J., Clack, G., Howell, A., Cuzick, J., Mackey, J., Beckmann, M. W., & Coleman, R. E.
Commentary by Sophie Trotter and Janet Brown
Section Fourteen: Surgery for Metastatic Disease
46. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
Rajendra Badwe, Rohini Hawaldar, Nita Nair, Rucha Kaushik, Vani Parmar, Shabina Siddique, Ashwini Budrukkar, Indraneel Mittra, Sudeep Gupta
Commentary by Urvashi Jain, Ashutosh Kothari and Rajendra Badwe
Section Fifteen: Breast Cancer in Pregnancy / Prophylactic surgery for family history
47. Treatment of breast cancer during pregnancy: an observational study
Loibl S, Han SN, Minckwitz GV, Bontenbal M, Ring A, Giermek J et al
Commentary by Lydia Newman, Chris Coyle, Avi Agrawal and Edward St John
48. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Ellen R Copson, Tom C Maishman, Will J Tapper, Ramsey I Cutress, Stephanie Greville-Heygate, Douglas G Altman et al Commentary by Wilson Cheah Pui Fui, Camellia Richards, Constantinos Savva and Ramsey Cutress
49. Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer.
Hartmann L., Schaid D., Woods J., Crotty T., Myers J., Arnold P.et al
Commentary by Hamza Ikram and Lynda Wyld
50. Wire- and magnetic-seed-guided localization of impalpable breast lesions: iBRA-NET localisation study (Arm 1)
Rajiv V Dave, Emma Barrett, Jenna Morgan, et al on behalf of the iBRA-NET Localisation Study collaborative
Commentary by Iram Hassan, Samantha Chen, Masooma Zaidi, Peter A Barry and Edward St John
Biography
Lynda Wyld is Professor of Surgical Oncology at the University of Sheffield and a Consultant Oncoplastic Surgeon at Doncaster and Bassetlaw Teaching Hospitals. She is the Past President of the British Association of Surgical Oncology (BASO) and Past Chair of the European Society of Surgical Oncology (ESSO) Education Committee and is a Trustee of the Association of Breast Surgery (ABS).
Ramsey Cutress is Professor of Breast Surgery at University of Southampton and a Consultant Surgeon at University Hospital Southampton. He is Chair of the Association of Breast Surgery (ABS) Academic and Research Committee, Course Director for the ABS Advanced Skills in Breast Disease Management course, Head of the School for Clinical Academic Training at the Wessex Deanery and breast disease subspecialty editor for the Annals of the Royal College of Surgeons of England, demonstrating his interests in research and teaching.
Jenna Morgan Jenna is an NIHR Advanced Fellow Breast Surgery at the University of Sheffield and a Consultant Oncoplastic Surgeon at the Jasmine Breast Unit in Doncaster, UK. She is Past Chair of the Mammary Fold Academic Committee of the ABS. She is a clinical academic with an interest in mixed methods research, geriatric oncology and the psychology or ageing in healthcare settings.
